Repare Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2017
Net Income	-93.8	-29.05	-106.91	-53.42	-27.22	Upgrade
Depreciation & Amortization	4.15	4.18	3.34	1.79	0.97	Upgrade
Share-Based Compensation	25.06	19.69	12.83	2.54	0.51	Upgrade
Other Operating Activities	-62.57	5.49	4.94	43.01	7.31	Upgrade
Operating Cash Flow	-127.16	0.32	-85.8	-6.08	-18.43	Upgrade
Capital Expenditures	-1.94	-0.6	-1.65	-2.24	-1.3	Upgrade
Change in Investments	79.98	-175.18	-0.03	-7.53	0	Upgrade
Investing Cash Flow	78.04	-175.78	-1.68	-9.76	-1.3	Upgrade
Share Issuance / Repurchase	0.84	0.88	95.56	247.84	0	Upgrade
Other Financing Activities	-	-	-	-	103.24	Upgrade
Financing Cash Flow	0.84	0.88	95.56	247.84	103.24	Upgrade
Exchange Rate Effect	0.02	-0.33	-0.05	-0.6	0.57	Upgrade
Net Cash Flow	-48.25	-174.91	8.03	231.39	84.08	Upgrade
Free Cash Flow	-129.1	-0.28	-87.45	-8.32	-19.73	Upgrade
Free Cash Flow Margin	-252.47%	-0.21%	-1150.61%	-6163.70%	-	Upgrade
Free Cash Flow Per Share	-3.07	-0.01	-2.31	-0.41	-12.91	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).